title: It is time to move forward with Waldenström!
abstract: In this issue of Blood, Roccaro et al demonstrate high expression of C-X-C chemokine receptor type 4 (CXCR4) mutation in Waldenström macroglobulinemia (WM), a marker of tumor aggression and drug resistance. In vivo analysis with an anti-CXCR4 antibody reversed this aggression, setting the stage for prospective studies in this forgotten disease.
authors: OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER.
authors: Yvonne A
authors: YA
authors: Efebera
mesh_terms: D000818:Animals; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D020125:Mutation, Missense; D019718:Receptors, CXCR4 / Q000378:metabolism*; D008258:Waldenstrom Macroglobulinemia / Q000378:metabolism*
chemical_list: C527276:CXCR4 protein, human; D004791:Enzyme Inhibitors; D019718:Receptors, CXCR4